
    
      This is an observational follow-up study of subjects who participated in previous Phase 1 and
      Phase 3 clinical trials of AAV2-hRPE65v2 gene therapy (voretigene neparvovec-rzyl) to
      evaluate long term durability and safety for 15 years after subretinal administration.
    
  